Indication
Soft Tissue Sarcoma
177 clinical trials
191 products
37 drugs
Clinical trial
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2024-12-15
Product
LOXO-292Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue TumorsStatus: Recruiting, Estimated PCD: 2025-07-12
Product
INT230-6Clinical trial
A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)Status: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Product
Surufatinib and TislelizumabClinical trial
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.Status: Recruiting, Estimated PCD: 2025-04-30
Product
BT-001Product
PembrolizumabProduct
EribulinProduct
89Zr-DFO-girentuximabProduct
TrabectedinProduct
PazopanibClinical trial
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIXStatus: Recruiting, Estimated PCD: 2025-12-08
Clinical trial
An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid TumorsStatus: Completed, Estimated PCD: 2023-04-25
Product
SurufatinibClinical trial
A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null TumorsStatus: Terminated, Estimated PCD: 2023-12-19
Product
CFT8634Product
TQB2858Clinical trial
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Checkpoint InhibitorClinical trial
Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-03-31
Product
AdAPT-001Clinical trial
First-in-man Clinical Trial to Assess Safety and Tolerability of CEB-01 PLGA Membrane in Patients With Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma After SurgeryStatus: Active (not recruiting), Estimated PCD: 2025-05-15
Product
CEB-01Product
PBA-0405Clinical trial
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0405 in Patients With Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2025-12-31
Product
DoxorubicinProduct
Onfekafusp alfaProduct
CamsirubicinClinical trial
A Phase 1b, Open-label, Dose-escalation Clinical Study Evaluating the Safety of Camsirubicin With Prophylactic Pegfilgrastim in the Treatment of Advanced Soft Tissue SarcomasStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial SarcomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
AL3818Clinical trial
A Dose Finding Study of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Combination With Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
DacarbazineProduct
L19TNFProduct
DOXORUBICINProduct
CEB-01 membraneClinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-03-01
Product
IrinotecanProduct
LurbinectedinProduct
HFB301001Clinical trial
A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid SarcomaStatus: Recruiting, Estimated PCD: 2029-01-28
Product
TazemetostatProduct
PlaceboProduct
OlaratumabClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2018-12-05
Clinical trial
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
An Open Label, Phase Ib/II Trial of LVGN6051 Combined With Anlotinib in the Treatment of Locally Advanced, Metastatic or Recurrent Refractory Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2025-03-19
Product
ChiauranibClinical trial
An Open-label, Multicenter, Phase II Study of Chiauranib Capsule in Patients With Advanced or Unresectable Soft Tissue Sarcoma Previously Failed to Standard of Care TreatmentStatus: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Phase 1/2 Study of YH001 in Combination With Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic SarcomaStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Product
YH001Product
EnvafolimabClinical trial
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue SarcomaStatus:
Product
CYT-0851Product
LVGN6051Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue TumorsStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase 1B/2 Study Of Liposomal Annamycin (L-Annamycin) In Subjects With Previously Treated Soft-Tissue Sarcomas With Pulmonary MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid MalignanciesStatus: Not yet recruiting, Estimated PCD: 2026-01-25
Product
ToripalimabProduct
ILB-2109Product
Liposomal AnnamycinProduct
Tigilanol TiglateClinical trial
A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall.Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-07-27
Product
SeclidemstatClinical trial
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select SarcomasStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Product
TinostamustineClinical trial
A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)Status: Completed, Estimated PCD: 2021-01-07
Clinical trial
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard TreatmentsStatus: Completed, Estimated PCD: 2021-05-06
Product
TopotecanClinical trial
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma PatientsStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma - CEP-2Status: Terminated, Estimated PCD: 2023-05-01
Product
NOX66Product
IP-001Clinical trial
An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK510 for Patients With Osteosarcoma and Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-09-01
Product
NK510Product
[Ga-68]-PNT6555Product
[Lu-177]-PNT6555Clinical trial
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)Status: Recruiting, Estimated PCD: 2029-10-01
Product
Systemic TreatmentProduct
ADI PEG20Clinical trial
ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 TrialStatus: Recruiting, Estimated PCD: 2027-12-30
Product
CyclophosphamideClinical trial
An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04)Status: Completed, Estimated PCD: 2021-07-02
Product
LTX-315 + TILsClinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)Status: Withdrawn, Estimated PCD: 2026-05-31
Drug
AtezolizumabDrug
UTD1Clinical trial
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway AlterationStatus: Recruiting, Estimated PCD: 2026-06-01
Product
AbemaciclibClinical trial
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone SarcomaStatus: Recruiting, Estimated PCD: 2025-09-30
Drug
cyclophosphamideProduct
attIL2-T cellsClinical trial
A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune MicroenvironmentStatus: Terminated, Estimated PCD: 2023-03-04
Product
ItacitinibClinical trial
A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced SarcomasStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
APX005MClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolStatus: Recruiting, Estimated PCD: 2027-09-30
Product
EnsartinibClinical trial
A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue SarcomasStatus: Active (not recruiting), Estimated PCD: 2025-02-01
Drug
SelinexorProduct
ErdafitinibProduct
LarotrectinibProduct
OlaparibProduct
PalbociclibProduct
SamotolisibProduct
SelpercatinibClinical trial
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesStatus: Recruiting, Estimated PCD: 2024-12-01
Drug
TivozanibProduct
SelumetinibProduct
TipifarnibProduct
UlixertinibProduct
VemurafenibClinical trial
Phase II Study of Niraparib in Soft Tissue Sarcoma Patients With Altered DNA Damage RepairStatus: Active (not recruiting), Estimated PCD: 2026-08-01
Product
NiraparibClinical trial
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic CancerStatus: Recruiting, Estimated PCD: 2025-09-30
Product
LY2880070Drug
GemcitabineDrug
AN0025Product
CobimetinibClinical trial
Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)Status: Recruiting, Estimated PCD: 2027-12-31
Product
T cellsProduct
VinorelbineProduct
VismodegibDrug
EntrectinibProduct
NivolumabProduct
FulvestrantClinical trial
A Phase I/II Trial of Neoadjuvant ADI-PEG 20 in Combination With Ifosfamide and Radiotherapy in Soft Tissue Sarcoma (STS)Status: Recruiting, Estimated PCD: 2026-01-15
Clinical trial
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Product
CabozantinibProduct
IpilimumabClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 MutationsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
IvosidenibProduct
IfosfamideProduct
MesnaClinical trial
A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Nanoplexed Poly I:C BO-112Clinical trial
A Phase 1/2 Study of Nab-Sirolimus With Pazopanib (VOTRIENT®) in Patients With Advanced Nonadipocytic Soft-Tissue SarcomasStatus: Active (not recruiting), Estimated PCD: 2022-11-17
Clinical trial
An Open-Label, Phase II Efficacy Trial of Doxorubicin in Combination With Dual Checkpoint Blockade Using Zalifrelimab (AGEN1884) or Botensilimab (AGEN1181) With Balstilimab (AGEN2034) for Advanced or Metastatic Soft Tissue SarcomasStatus: Recruiting, Estimated PCD: 2024-11-24
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle GenesStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Drug
FOLFOXIRIClinical trial
A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
AnlotinibClinical trial
A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable DiseaseStatus: Recruiting, Estimated PCD: 2025-01-09
Product
LetrozoleProduct
Poly ICLCProduct
Recombinant Flt3 LigandDrug
AbraxaneClinical trial
Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent TumorsStatus: Active (not recruiting), Estimated PCD: 2013-01-19
Product
melphalanDrug
TiragolumabProduct
PertuzumabClinical trial
Phase Ib/II Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination With Radiotherapy in Soft Tissue Sarcomas and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2025-11-30
Product
PM14Clinical trial
Pembrolizumab Alone and in Combination(s) With MK-0482 and MK-4830 Via Intratumoral Injection in Patients With Head and Neck Squamous Cell Carcinoma or Soft Tissue Sarcoma Prior to Planned Surgical InterventionStatus: Completed, Estimated PCD: 2023-06-22
Product
MK-0482 + PembrolizumabProduct
MK-4830 + PembrolizumabClinical trial
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)Status: Active (not recruiting), Estimated PCD: 2019-06-30
Clinical trial
TAEST16001 in Patients With Soft Tissue Sarcoma With Positive NY-ESO-1 Expression (Genotype: HLA-A*02:01): an Multi-center, Open-label and Single Arm Phase II StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Product
NY-ESO-1Clinical trial
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
AldesleukinClinical trial
A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated LiposarcomaStatus: Recruiting, Estimated PCD: 2027-05-23
Drug
EtrumadenantProduct
ZimberelimabClinical trial
a 3 Arm Randomized Study on Health-related Quality of Life of Elderly Patients With Advanced Soft Tissue Sarcoma Undergoing Doxorubicin Alone Every Three Weeks or Doxorubicin Weekly or Cyclophosphamide Plus Predniso(lo)ne TreatmentStatus: Terminated, Estimated PCD: 2023-09-22
Product
PrednisoloneProduct
PrednisoneClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic AlterationsStatus: Recruiting, Estimated PCD: 2024-09-30
Drug
TrastuzumabDrug
fludarabineClinical trial
Sarcomas and DDR-Inhibition; a Neoadjuvant Phase I Combined Modality Study.Status: Recruiting, Estimated PCD: 2026-03-01
Product
AZD1390Clinical trial
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung CancerStatus: Completed, Estimated PCD: 2022-07-08
Product
Pegylated Arginine DeiminaseDrug
DocetaxelClinical trial
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced SarcomasStatus: Recruiting, Estimated PCD: 2024-04-28
Product
Pembrolizumab + CabozantinibDrug
busulfanClinical trial
A Pilot Study Evaluating the Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab in Patients With Metastatic or Unresectable Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2021-11-16
Clinical trial
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2020-09-30
Clinical trial
Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the ExtremityStatus: Completed
Product
Tumor Necrosis FactorClinical trial
A Pilot Study of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in AdultsStatus: Recruiting, Estimated PCD: 2024-08-31
Product
AscorbateClinical trial
Phase I/II Randomized Clinical Trial of Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue SarcomasStatus: Recruiting, Estimated PCD: 2026-05-31
Product
SelinexorClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK FusionsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
Trastuzumab EmtansineClinical trial
A Prospective Phase II Study of PARP Inhibition and Check Point-inhibition Immunotherapy With Concurrent Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic or Advanced SarcomaStatus: Recruiting, Estimated PCD: 2026-08-30
Product
Camrelizumab + FluzoparibClinical trial
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue SarcomasStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase I Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic SarcomaStatus: Recruiting, Estimated PCD: 2027-11-01
Product
SBRT + MEDI5752Clinical trial
Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)Status: Not yet recruiting, Estimated PCD: 2026-02-01
Product
Aminolevulinic AcidClinical trial
Phase I/II Randomized Clinical Trial of Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and OsteosarcomaStatus: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Phase II Multicenter Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.Status: Recruiting, Estimated PCD: 2024-09-30
Product
TMZClinical trial
A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)Status: Recruiting, Estimated PCD: 2026-01-01
Product
HDM201Clinical trial
Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2025-06-01
Product
4-1BBζ EGFR806-EGFRtClinical trial
Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at ProgressionStatus: Not yet recruiting, Estimated PCD: 2028-10-01
Product
DostarlimabClinical trial
Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Single-arm, Single-center, Exploratory Phase II Study of Surufatinib in Patients With Soft Tissue Sarcoma Who Have Failed Anthracycline-containing Chemotherapy and Who Have Been Successfully Targeted With Antivascular AgentsStatus: Not yet recruiting, Estimated PCD: 2024-08-15
Drug
CisplatinClinical trial
An Open, Multi-center, Randomized, Phase II Study of Adriamycin and Ifosfamide Combined With Sintilimab in the Treatment of Advanced or Unresectable Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2025-12-30
Product
SintilimabProduct
AdriamycinClinical trial
Phase III Study Comparing Trabectedin (T) Versus T Plus tTF-NGR to Entrap T Inside the Tumor in Patients With Metastatic and/or Refractory Soft Tissue Sarcoma (STS)Status: Recruiting, Estimated PCD: 2025-12-01
Drug
TrabectedinProduct
tTF-NGRProduct
NilotinibProduct
CeritinibProduct
CapmatinibProduct
LapatinibProduct
TrametinibProduct
Trametinib and DabrafenibProduct
Olaparib + DurvalumabProduct
GlasdegibProduct
TAS-120Clinical trial
Sequential Neoadjuvant Ifosfamide and Doxorubicin in Localized High-grade Soft Tissue Sarcoma of Extremities and Trunk WallStatus: Recruiting, Estimated PCD: 2026-09-01
Drug
R-CHOPClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway MutationsStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Product
AlectinibDrug
AlpelisibClinical trial
An Open, Multicenter, Randomized, Phase II Study of Toripalimab Combined With CAV/IE Regimen in Patients With Advanced or Unresectable Bone and Soft Tissue Sarcomas Who Failed Standard TreatmentStatus: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
Phase I/II Randomized Trial of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue SarcomasStatus: Recruiting, Estimated PCD: 2025-06-20
Product
LB-100Product
AnastrozoleClinical trial
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Talimogene LaherparepvecClinical trial
Phase II, Single-arm Clinical Trial Evaluating Efficacy and Safety of Pembrolizumab in Combination With a Soluble LAG-3 Protein, Eftilagimod Alpha, and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcomas (EFTISARC-NEO)Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance:A Multicenter Retrospective StudyStatus: Completed, Estimated PCD: 2023-08-29
Product
FruquintinibClinical trial
A Single-arm, Multicentre, Phase II Clinical Trial of Anlotinib Maintenance Treatment After First-line Anthracycline-based Chemotherapy in Advanced Soft Tissue Sarcoma (ALTER-S006)Status: Recruiting, Estimated PCD: 2023-12-30
Product
AnlotinibDrug
FilgrastimClinical trial
Utility of 18F-DOPA PET/MRI Metrics as a Biomarker for Treatment Response Assessment in Sarcoma Patients: A Pilot StudyStatus: Recruiting, Estimated PCD: 2024-07-01
Product
Fluorodopa F 18Clinical trial
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled TrialStatus: Completed, Estimated PCD: 2023-08-18
Product
Tranexamic AcidClinical trial
BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastStatus:
Drug
DeltaRex-GClinical trial
A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in LeiomyosarcomaStatus: Recruiting, Estimated PCD: 2024-07-01
Drug
LurbinectedinClinical trial
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersStatus: Recruiting, Estimated PCD: 2027-12-30
Product
HBI 0201-ESO TCRTClinical trial
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable SarcomaStatus: Completed, Estimated PCD: 2019-04-01
Clinical trial
A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.Status: Recruiting, Estimated PCD: 2026-02-01
Drug
interleukin-2Clinical trial
SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN as First Line Treatment of Advanced Soft Tissue Sarcoma (STS)Status: Recruiting, Estimated PCD: 2024-12-31
Drug
T-VECClinical trial
Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
RibociclibProduct
EverolimusClinical trial
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing SarcomaStatus: Recruiting, Estimated PCD: 2025-12-31
Product
TalazoparibClinical trial
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2032-06-21
Product
MESNAProduct
B7-H3 CAR T cellsClinical trial
Phase 2 Study of Ipilimumab Plus Nivolumab in Combination With Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-01-31
Clinical trial
A Phase II Study of Oral ENMD-2076 Administered to Patients With Advanced/Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2015-12-01
Product
ENMD-2076Clinical trial
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2027-02-02
Product
LVGN3616Clinical trial
Preoperative Moderately Fractionated Intensity-modulated Radiotherapy (IMRT) With/Without Concurrent Fluzoparil for Locally Extremity or Trunk SarcomaStatus: Recruiting, Estimated PCD: 2026-04-30
Product
FluzoparibClinical trial
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or DeletionsStatus: Not yet recruiting, Estimated PCD: 2029-02-01
Product
Nab-SirolimusClinical trial
Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined With Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refractory Solid Tumors With Retinoblastoma DeficiencyStatus: Recruiting, Estimated PCD: 2024-08-01
Product
TAS-116Clinical trial
The Efficacy and Safety of Cadonilimab(AK104) With Adriamycin for First-line Treatment of Advanced Soft Tissue Sarcoma: a Multicenter, Single-arm, Phase II Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2027-03-31
Drug
CadonilimabClinical trial
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-03-15
Drug
RegorafenibDrug
VarlilumabClinical trial
Efficacy and Safety of Cadonilimab Combined With Anlotinibin in the Treatment of Advanced or Metastatic Soft Tissue Sarcoma With Previous First-Line Standard Treatment Failure.Status: Recruiting, Estimated PCD: 2024-08-01
Product
CandonilimabClinical trial
A Single-Center Phase I Dose Escalation/Response Trial to Evaluate Safety, Tolerability, and Anti-Tumor Efficacy of Intra-Arterial CBL0137 for Patients With Advanced Extremity Melanoma or SarcomaStatus: Terminated, Estimated PCD: 2024-01-16
Product
CBL0137Clinical trial
Phase I/II Study of Gemcitabine and Docetaxel Combined With Immune Checkpoint Blockade (Retifanlimab) in Patients With Advanced Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2025-09-29
Product
RetifanlimabClinical trial
A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional ChemotherapyStatus: Recruiting, Estimated PCD: 2024-06-30
Product
No InterventionClinical trial
A Phase II Clinical Trial Evaluating the Safety and Efficacy of Radioactive Particle and Fluzoparib Combination Therapy in the Treatment of Advanced Unresectable Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid CancersStatus: Withdrawn, Estimated PCD: 2025-04-30
Product
RegorafenibClinical trial
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young AdultsStatus: Active (not recruiting), Estimated PCD: 2024-01-26
Product
nab-PaclitaxelClinical trial
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. TRUST StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Bintrafusp alfaDrug
doxorubicinClinical trial
LINNOVATE: A Phase 1/2 Study of Safety/Efficacy Using LURBINECTEDIN, Combined With IPILIMUMAB, and NIVOLUMAB for Advanced Soft Tissue SarcomasStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
An Open Label, Single Centre, Single Arm, Prospective Feasibility Study Evaluating the Effectiveness of Near-infrared Fluorescence (NIRF) Using Indo-cyanine Green (ICG) in Minimally Invasive Paediatric Oncology Surgery (MIS)Status: Completed, Estimated PCD: 2022-09-30
Product
Indocyanine greenClinical trial
Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
4-1BBζ B7H3-EGFRt-DHFRProduct
second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tGClinical trial
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue SarcomasStatus: Completed, Estimated PCD: 2019-01-22
Clinical trial
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue SarcomasStatus: Active (not recruiting), Estimated PCD: 2023-02-07
Drug
mFOLFOX6Clinical trial
In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues SarcomasStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas: Feasibility Steps Toward Personalized Medicine.Status: , Estimated PCD: 2023-12-01
Product
18F-FAZAClinical trial
A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Risk Soft Tissue SarcomasStatus: Completed, Estimated PCD: 2023-06-08
Clinical trial
A Pilot Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Treatment of Relapsed or Refractory Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)Status: Active (not recruiting), Estimated PCD: 2023-08-27
Drug
NavtemadlinClinical trial
An Open, Single Arm and Early Clinical Study of TAEST16001 in the Treatment of Solid Tumor Mainly Containing Soft Tissue Sarcoma With Positive Expression of Tumor Antigen NY-ESO-1 (HLA-A * 02:01)Status: Active (not recruiting), Estimated PCD: 2022-04-15
Product
TAEST16001Clinical trial
Randomized Phase III Study of Oral Cyclophosphamide vs Doxorubicin in 65 Years or Older Patients With Advanced or Metastatic Soft Tissue Sarcoma: a UNICANCER/GERICO Multicenter ProgramStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-08-12
Product
Durvalumab and TremelimumabClinical trial
Phase II Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic SarcomasStatus: Recruiting, Estimated PCD: 2024-07-28
Clinical trial
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2024-02-15
Clinical trial
A Phase I Trial of Dendritic Cell Vaccination for Children and Adults With SarcomaStatus: Active (not recruiting), Estimated PCD: 2019-09-10
Product
Dendritic Cells VaccineProduct
Lysate of TumorProduct
ImiquimodClinical trial
Phase 1b/2 Trial Using Neoadjuvant Lurbinectedin With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas of Extremity, Trunk, and RetroperitoneumStatus: Not yet recruiting, Estimated PCD: 2026-01-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF ComplexStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
A Single Arm, Single Center, Prospective Clinical Study of Anrotinib Hydrochloride Combined With Doxorubicin in the Neoadjuvant Treatment of High-grade Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-09-30
Product
AnrotinibClinical trial
A Single-arm, Open, Phase II Study of Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-03-01
Product
Anlotinib + ToripalimabClinical trial
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.Status: Active (not recruiting), Estimated PCD: 2024-02-15
Product
Blood and tumor samplesClinical trial
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study.Status: Recruiting, Estimated PCD: 2024-06-01
Product
Nivolumab + RelatlimabClinical trial
Combining Epigenetic And Immune Therapy to Beat Cancer. CAIRE StudyStatus: Recruiting, Estimated PCD: 2023-07-01
Clinical trial
Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption ApproachStatus: Recruiting, Estimated PCD: 2023-12-01
Product
Ga-68-PSMA-11Product
Lu-177-ITG-PSMA-1Clinical trial
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma PatientsStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive ChemotherapyStatus: Terminated, Estimated PCD: 2021-09-01
Product
GenisteinClinical trial
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-07-17
Product
DexrazoxaneClinical trial
Surufatinib Combined With Envafolimab Followed by Surufatinib as Second or More - Line Therapy for Advanced Soft Tissue Sarcoma in a Single-arm, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2026-02-02
Product
Surufatinib + EnvafolimabClinical trial
Phase 1b/2 Neoadjuvant High Dose Ascorbate With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas of Extremity, Trunk and RetroperitoneumStatus: Active (not recruiting), Estimated PCD: 2022-06-03
Clinical trial
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803Status: Completed, Estimated PCD: 2021-06-01
Product
Natural Killer CellsProduct
ALT803Clinical trial
Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.Status: Completed, Estimated PCD: 2020-11-19
Product
Trabectedin + DurvalumabClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic AlterationsStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
A Pilot Study of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas Including AdolescentsStatus: Withdrawn, Estimated PCD: 2025-05-31
Clinical trial
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Single-arm, Open, Exploratory Clinical Study on the Safety and Efficacy of Piamprilimab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-03-31
Product
PiamprimabClinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver DysfunctionStatus: Active (not recruiting), Estimated PCD: 2018-11-29
Product
RomidepsinClinical trial
An Open Label Phase 2 Study on Propranolol and Pembrolizumab in Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma - a Scandinavian Sarcoma Group CollaborationStatus: Recruiting, Estimated PCD: 2028-01-01
Product
PropranololClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 MutationsStatus: Active (not recruiting), Estimated PCD: 2022-06-30
Clinical trial
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
The Use of Liposomal Bupivacaine (Exparel) in Soft Tissue Sarcoma ResectionStatus: Terminated, Estimated PCD: 2019-06-11
Product
Liposomal BupivacaineDrug
cetuximabProduct
TemsirolimusProduct
Valproic AcidClinical trial
A Study to Assess Topoisomerase II Alpha (TOPO2A) as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2021-06-10
Clinical trial
Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasStatus: Recruiting, Estimated PCD: 2025-06-30
Product
SunitinibDrug
EpirubicinClinical trial
A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin ( (Doxil®) in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue SarcomasStatus: Recruiting, Estimated PCD: 2025-05-03
Product
PeposertibClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene AlterationsStatus: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2014-04-09
Product
INNO-206Clinical trial
Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients With Soft Tissue SarcomaStatus: , Estimated PCD: 2026-05-15
Clinical trial
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.Status: Not yet recruiting, Estimated PCD: 2030-12-31
Clinical trial
The METROPHOLYS Study Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas Randomized, Controlled Open Label Clinical TrialStatus: Terminated, Estimated PCD: 2024-05-23